316 related articles for article (PubMed ID: 22042278)
21. Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants.
Maggi M; Chiarelli LR; Valentini G; Scotti C
PLoS One; 2015; 10(2):e0117025. PubMed ID: 25664771
[TBL] [Abstract][Full Text] [Related]
22. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
Holcenberg JS
Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
24. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
Nguyen HA; Su Y; Lavie A
J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
[TBL] [Abstract][Full Text] [Related]
25. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.
Offman MN; Krol M; Patel N; Krishnan S; Liu J; Saha V; Bates PA
Blood; 2011 Feb; 117(5):1614-21. PubMed ID: 21106986
[TBL] [Abstract][Full Text] [Related]
26. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
27. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
28. [Biological properties of an asparaginase-glutaminase preparation from Pseudomonas fluorescens in cell cultures].
Kondrat'eva NA; Dobrynin IaV; Merkulov MF
Antibiotiki; 1978 Feb; 23(2):122-5. PubMed ID: 415658
[TBL] [Abstract][Full Text] [Related]
29. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Qiao J; Qi L; Mu X; Chen Y
Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
[TBL] [Abstract][Full Text] [Related]
30. Effect of Acinetobacter glutaminase-asparaginase treatment on free amino acids in mouse tissues.
Holcenberg JS; Tang E; Dolowy WC
Cancer Res; 1975 May; 35(5):1320-5. PubMed ID: 1091350
[TBL] [Abstract][Full Text] [Related]
31. Glutaminase free l-asparaginase from Vibrio cholerae: Heterologous expression, purification and biochemical characterization.
Radha R; Arumugam N; Gummadi SN
Int J Biol Macromol; 2018 May; 111():129-138. PubMed ID: 29307802
[TBL] [Abstract][Full Text] [Related]
32. [Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia].
Pawińska K; Balwierz W; Sztefko K; Czogała M
Przegl Lek; 2006; 63(1):44-6. PubMed ID: 16892900
[TBL] [Abstract][Full Text] [Related]
33. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
Sindhu R; Manonmani HK
Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
[TBL] [Abstract][Full Text] [Related]
34. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
35. [Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase].
Wlazłowski M; Celińska W; Maciejka-Kapuścińska L; Płoszyńska A; Idczak E
Pol Tyg Lek; 1994 Mar 21-28; 49(12-13):296-7. PubMed ID: 7808958
[TBL] [Abstract][Full Text] [Related]
36. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.
Borek D; Kozak M; Pei J; Jaskolski M
FEBS J; 2014 Sep; 281(18):4097-111. PubMed ID: 25040257
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.
Warrell RP; Arlin ZA; Gee TS; Chou TC; Roberts J; Young CW
Cancer Treat Rep; 1982 Jul; 66(7):1479-85. PubMed ID: 7046929
[TBL] [Abstract][Full Text] [Related]
39. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
40. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
